Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701443 | 0.83 | CHRM5 (0.34) | — | |
| SCHEMBL13825880 | 0.77 | LTA4H (0.34) | — | |
| SCHEMBL30491803 | 0.77 | LTA4H (0.34) | — | |
| SCHEMBL16853098 | 0.77 | LTA4H (0.34) | — | |
| SCHEMBL28982691 | 0.73 | GAA (0.38) | GAADPP4USP2 | |
| SCHEMBL19356031 | 0.72 | GAA (0.33) | GAADPP4 | |
| Hydrochloric Acid SCHEMBL6788921 | 0.71 | GAA (0.37) | GAADPP4USP2 | |
| SCHEMBL18525558 | 0.71 | GAA (0.35) | GAADPP4 | |
| SCHEMBL6282596 | 0.71 | — | — | |
| SCHEMBL13733461 | 0.69 | DPP4 (0.36) | GAADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | GAA 3762/4885DPP4 4222/4885USP2 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.